Biosimilars Cash-rich Gilead Sciences has been expected to make acquisitions, particularly after Norbert Bischofberger, executive vice-president of research and development, said in an interview with the Financial Times late last year: “We have our eye on the external world — we have incredible cash flows and we are looking for opportunities.” 9 April 2016